GLP‑1 medicines have moved from metabolic workhorses to front-page news. Originally designed for diabetes, they now sit at the centre of conversations about obesity, cardiovascular risk – and increasingly, brain and cancer biology. Beneath the headlines, two distinct questions are emerging for R&D and portfolio leaders: In neurodegeneration, are GLP‑1s genuinely touching disease mechanisms in Alzheimer’s and Parkinson’s, or are they mainly cleaning up upstream metabolic and

For decades, families affected by rare diseases have heard the same heartbreaking message: ‘There is no approved treatment yet.’ In 2026, that story is finally changing. From the first-ever approval for Menkes disease to a landmark FDA policy shift for gene therapies, the rare disease landscape is transforming at a pace never seen before. Here’s what you need to know.

If you read recent scientific reviews on artificial intelligence (AI) in the pharmaceutical industry, you get a clear message: AI is transforming drug discovery, clinical development, manufacturing, and safety.¹⁻⁵ However, if you talk to bench scientists, clinical teams, or data scientists over coffee, you often hear a more complicated story: pockets of impressive success, a lot of incremental improvements, and quite a few stalled pilots. Both perspectives are true. They’re j

For generations, treating cancer has relied on a pretty brutal calculus: hit the body hard and hope the cancer dies first. Traditional chemotherapy is essentially a scorched-earth strategy. It works, but at a massive cost—wrecking the heart, gut, and nervous system along with the tumour. . For decades, researchers have chased a deceptively simple question: What if we could send the drug only where it’s actually needed? Antibody-drug conjugates, or ADCs, are the most promising